Access Pharmaceuticals, Inc. (OTCBB: ACCP) of Dallas, TX has out-licensed the China rights to ProLindac™, its platinum cancer drug currently in Phase II trials, to Jiangsu Aosaikang Pharmaceutical Co., Ltd. of Nanking (ASK). ASK will be responsible for obtaining SFDA approval of the drug in China. Perhaps the most interesting facet of the deal is that ASK agreed to conduct Phase II trials of ProLindac in China for colorectal cancer and one other indication, still to be determined. Access intends to use the data from these trials to proceed directly to Phase III trials of ProLindac in the West. More details...

Stock Symbols: (OTCBB: ACCP) (NYSE: SNY)